TY - JOUR
T1 - I-fibrinogen as an oncophilic radiodiagnostic agent
T2 - Distribution kinetics in tumour-bearing mice
AU - Krohn, K. A.
AU - DeNardo, S. J.
AU - Wheeler, D. W.
AU - DeNardo, G. L.
N1 - Funding Information:
We wish to express our appreciation to Show-Mei Huang, Jeanne Meyers, David Vera and Mary Virdeh for technical assistance, to Anne-Line Jansholt for separating the fibrinogen, and to Dr David Goodwin for his assistance in establishing the KHJJ tumour model. This research was supported by American Cancer Society Grant No. DT-45 and by General Research Support Funds from the National Institute of Health.
PY - 1977/8
Y1 - 1977/8
N2 - Fibrinogen radioiodinated by the iodine monochloride method was tested as a tumour radiodiagnostic agent in mice. The I-fibrinogen cleared from the blood of tumour-bearing mice more rapidly than from that of normal mice, but it cleared from the whole body more slowly, suggesting it accumulated in a substantial tumour-related compartment in the abnormal mice. The tumour concentration steadily increased for 4 h after injection, at which time it reached a peak concentration of 11-4% of the injected dose/g. This concentration was higher than the peak concentration for Ga-citrate (not reached until 24 h) or any other oncophilic radiopharmaceutical tested in this tumour model. The early accumulation is consistent with the use of 123I as a tracer label for fibrinogen. A combination of the large tumour concentration of I-fibrinogen, an increased catabolic rate induced by chemical modification, and the exceptional nuclear properties of 123I for scintigraphic imaging, could lead to a very useful radiodiagnostic procedure for cancer.
AB - Fibrinogen radioiodinated by the iodine monochloride method was tested as a tumour radiodiagnostic agent in mice. The I-fibrinogen cleared from the blood of tumour-bearing mice more rapidly than from that of normal mice, but it cleared from the whole body more slowly, suggesting it accumulated in a substantial tumour-related compartment in the abnormal mice. The tumour concentration steadily increased for 4 h after injection, at which time it reached a peak concentration of 11-4% of the injected dose/g. This concentration was higher than the peak concentration for Ga-citrate (not reached until 24 h) or any other oncophilic radiopharmaceutical tested in this tumour model. The early accumulation is consistent with the use of 123I as a tracer label for fibrinogen. A combination of the large tumour concentration of I-fibrinogen, an increased catabolic rate induced by chemical modification, and the exceptional nuclear properties of 123I for scintigraphic imaging, could lead to a very useful radiodiagnostic procedure for cancer.
UR - http://www.scopus.com/inward/record.url?scp=0017727834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017727834&partnerID=8YFLogxK
U2 - 10.1038/bjc.1977.182
DO - 10.1038/bjc.1977.182
M3 - Article
C2 - 911661
AN - SCOPUS:0017727834
SN - 0007-0920
VL - 36
SP - 227
EP - 234
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 2
ER -